Feasibility of Postexposure Prophylaxis (PEP) against Human Immunodeficiency Virus Infection after Sexual or Injection Drug Use Exposure: The San Francisco PEP Study

The feasibility of providing postexposure prophylaxis (PEP) after sexual or injection drug use exposures to human immunodeficiency virus (HIV) was evaluated. PEP was provided within 72 h to individuals with exposures from partners known to have or to be at risk for HIV infection. PEP consisted of 4...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of infectious diseases 2001-03, Vol.183 (5), p.707-714
Hauptverfasser:	Kahn, James O., Martin, Jeffrey N., Roland, Michelle E., Bamberger, Joshua D., Chesney, Margaret, Chambers, Donald, Franses, Karena, Coates, Thomas J., Katz, Mitchell H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged AIDS Anal intercourse Anti-HIV Agents - therapeutic use Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Antibodies Antiretrovirals Biological and medical sciences Contact Tracing Counseling Didanosine - therapeutic use Female HIV HIV infections HIV Infections - drug therapy HIV Infections - prevention & control Human immunodeficiency virus Human viral diseases Humans Infectious diseases Lamivudine - therapeutic use Major Articles Male Medical sciences Medications Men Middle Aged Nelfinavir - therapeutic use Patient Compliance Pharmacology. Drug treatments Post exposure prophylaxis Reverse Transcriptase Inhibitors - therapeutic use Risk Factors Risk-Taking Sexual transmission Sexually Transmitted Diseases, Viral - drug therapy Sexually Transmitted Diseases, Viral - prevention & control Substance Abuse, Intravenous - complications Time Factors USA, California, San Francisco Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Zidovudine - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!